03 Oct 2026, 15:02 IST
Piramal Pharma Limited
Motilal Oswal (MOFSL) · Buy
The report notes Piramal is expected to post a net loss in 2QFY27 despite 41.0% YoY EBITDA growth, and underwent a USFDA inspection at its Morpeth, UK facility with 7 observations.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.